<?xml version="1.0" encoding="UTF-8"?>
<HL7Messages MessageFormat="ORUR01" MessageCount="11" Version="2.3"><Message MsgID="1"><![CDATA[MSH|^~\&|PATHL7|VIHA|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516828|P|2.3|||ER|AL
PID||9039039033|1112200||EXCELLERIS^IPATIENT||19611202|F|||||(250)876-7676
ORC|RE||10-121-121200-DIM-0|||||||||90909^MDCARE^BOB
OBR|1||10-121-121200-DIM-0|DIM^D-Dimer|RT|20100217155300|20100217143000|||||||20100217155300||90909^MDCARE^BOB||||||20100217165603||HAEM3|F||^^^^^RT|90909^MDCARE^BOB
OBX|1|NM|7799-0^D-Dimer Quantitative||<0.50|mg/L FEU|0.00-0.49|N|||F|||20100217165602
NTE|||The D Dimer is not useful as a screening test in making the diagnosis of DVT/PE.\.br\A D Dimer result of less than 0.50 mg/L FEU has a negative predictive value of approximately 99% for the exclusion of Venous Thromboembolism, if clinical risk stratification indicates low or moderate risk of DVT or PE.\.br\
]]></Message><Message MsgID="2"><![CDATA[MSH|^~\&|PATHL7|LIFELABS|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516830|P|2.3|||ER|AL
PID||9061222333||GFC127369|EXCELLERIS^AAPATIENT||19521120|F|||||(604)944-4444
ORC|RE||10-121212444-GCM-1|||||||||90909^MDCARE^BOB
OBR|1||10-121212444-GCM-1|GCM^General Information||20100504093100|20100504093100|||||||20100504093100||90909^MDCARE^BOB||||||20100513112056||GENERAL|F|||C1747^GRANVILLE MEDICAL^CLINIC~90909^MDCARE^BOB
NTE|||DAY 3\.br\
ORC|RE||10-121212444-HP-1|||||||||90909^MDCARE^BOB
OBR|2||10-121212444-HP-1|HP^Hematology Panel||20100504093100|20100504093100|||||||20100504093100||90909^MDCARE^BOB||||||20100513112056||HAEM1|F|||C1747^GRANVILLE MEDICAL^CLINIC~90909^MDCARE^BOB
OBX|1|ST|6690-2^WBC||5.0|giga/L|4.0-10.0|N|||F|||20100513112056
OBX|2|ST|789-8^RBC||4.84|tera/L|3.80-4.80|A|||F|||20100513112056
OBX|3|ST|718-7^Hemoglobin||131|g/L|120-150|N|||F|||20100513112056
OBX|4|ST|4544-3^Hematocrit||0.40||0.35-0.43|N|||F|||20100513112056
OBX|5|ST|787-2^MCV||82|fl|82-98|N|||F|||20100513112056
OBX|6|ST|785-6^MCH||27.1|pg|27.5-33.5|A|||F|||20100513112056
OBX|7|ST|786-4^MCHC||329|g/L|305-365|N|||F|||20100513112056
OBX|8|ST|788-0^RDW||18.3|%|11.5-14.5|A|||F|||20100513112056
OBX|9|ST|777-3^Platelet Count||225|giga/L|150-400|N|||F|||20100513112056
OBX|10|ST|751-8^Neutrophils||3.2|giga/L|2.0-7.5|N|||F|||20100513112056
OBX|11|ST|731-0^Lymphocytes||1.3|giga/L|1.0-4.0|N|||F|||20100513112056
OBX|12|ST|742-7^Monocytes||0.4|giga/L|0.1-0.8|N|||F|||20100513112056
OBX|13|ST|711-2^Eosinophils||0.1|giga/L|0.0-0.7|N|||F|||20100513112056
OBX|14|ST|704-7^Basophils||0.0|giga/L|0.0-0.2|N|||F|||20100513112056
OBX|15|FT|6742-1^RBC Morphology||ELLIPTOCYTES      present        \.br\PLATELETS         normal\.br\||||||F|||20100513112056
OBX|16|FT|14869-2^Pathologist Comments||Reviewed by Pathologist\.br\Note 40 g / L increase in hemoglobin\.br\since 01 Feb 2010. Hb investigation to\.br\follow.\.br\||||||F|||20100513112056
ORC|RE||10-121212444-THALSCRN-1|||||||||90909^MDCARE^BOB
OBR|3||10-121212444-THALSCRN-1|THALSCRN^Thalassemia Screen||20100504093100|20100504093100|||||||20100504093100||90909^MDCARE^BOB||||||20100513112056||HAEM2|F|||C1747^GRANVILLE MEDICAL^CLINIC~90909^MDCARE^BOB
OBX|1|FT|X1051^Thalassemia Screen||Thalassemia work up to follow.\.br\||||||F|||20100513112056
ORC|RE||10-121212444-HBM-1|||||||||90909^MDCARE^BOB
OBR|4||10-121212444-HBM-1|HBM^Hemoglobin Investigation||20100504093100|20100504093100|||||||20100504093100||90909^MDCARE^BOB||||||20100513112056||HAEM2|F|||C1747^GRANVILLE MEDICAL^CLINIC~90909^MDCARE^BOB
OBX|1|ST|4551-8^HB A2||2.7|%|2.0-3.5|N|||F|||20100513112056
OBX|2|ST|4576-5^HB F||0.9|%|<2.0|N|||F|||20100513112056
OBX|3|FT|X514^HB HPLC||Reviewed by Pathologist\.br\High performance liquid chromatography\.br\analysis of hemoglobin is normal.\.br\||||||F|||20100513112056
ORC|RE||10-121212444-TSR-1|||||||||90909^MDCARE^BOB
OBR|5||10-121212444-TSR-1|TSR^TSH||20100504093100|20100504093100|||||||20100504093100||90909^MDCARE^BOB||||||20100513112056||CHEM11|F|||C1747^GRANVILLE MEDICAL^CLINIC~90909^MDCARE^BOB
OBX|1|ST|3016-3^TSH||4.4|mU/L|0.38-5.5|N|||F|||20100513112056
NTE|||TSH values of 3.5-5.5 may be associated\.br\with preclinical hypothyroidism in \.br\some cases.\.br\\.br\
ORC|RE||10-121212444-FSH-1|||||||||90909^MDCARE^BOB
OBR|6||10-121212444-FSH-1|FSH^Follicle Stimulating Hormone (FSH)||20100504093100|20100504093100|||||||20100504093100||90909^MDCARE^BOB||||||20100513112056||CHEM12|F|||C1747^GRANVILLE MEDICAL^CLINIC~90909^MDCARE^BOB
OBX|1|ST|2286-3^FSH||7.2|IU/L|||||F|||20100513112056
NTE|||Prepubertal:       <3.0 IU/L\.br\Follicular/Luteal: <9.0 IU/L\.br\Midcycle:         4.0 - 20.0 IU/L\.br\Postmenopausal:  20.0 - 135 IU/L\.br\
ORC|RE||10-121212444-PRL-1|||||||||90909^MDCARE^BOB
OBR|7||10-121212444-PRL-1|PRL^Prolactin||20100504093100|20100504093100|||||||20100504093100||90909^MDCARE^BOB||||||20100513112056||CHEM12|F|||C1747^GRANVILLE MEDICAL^CLINIC~90909^MDCARE^BOB
OBX|1|ST|2842-3^Prolactin||19.0|ug/L|<25|N|||F|||20100513112056
ORC|RE||10-121212444-ESD-1|||||||||90909^MDCARE^BOB
OBR|8||10-121212444-ESD-1|ESD^Estradiol||20100504093100|20100504093100|||||||20100504093100||90909^MDCARE^BOB||||||20100513112056||CHEM15|F|||C1747^GRANVILLE MEDICAL^CLINIC~90909^MDCARE^BOB
OBX|1|ST|14715-7^Estradiol||160|pmol/L|||||F|||20100513112056
ORC|RE||10-121212444-VARI-1|||||||||90909^MDCARE^BOB
OBR|9||10-121212444-VARI-1|VARI^Varicella Zoster Virus||20100504093100|20100504093100|||||||20100504093100||90909^MDCARE^BOB||||||20100513112056||REFER1|F|||C1747^GRANVILLE MEDICAL^CLINIC~90909^MDCARE^BOB
NTE|||Varicella Serology\.br\Sent to BC Centre for Disease Control\.br\(Prov Lab) Telephone: 1-877-747-2522.\.br\(1-877-PHSALAB)
]]></Message><Message MsgID="3"><![CDATA[MSH|^~\&|PATHL7|PHC|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516831|P|2.3|||ER|AL
PID||9111494949|21415047||EXCELLERIS^HHPATIENT||19550824|M|||||604-687-6123
ORC|RE||PB10-55-AP1156244-BMR-1|||||||||90909^MDCARE^BOB
OBR|1||PB10-55-AP1156244-BMR-1|BMR^Bone Marrow Report|||20100506090000|||||||20100506102700||90909^MDCARE^BOB||||||20100507162331||CELLPATH|F|||90909^MDCARE^BOB
OBX|1|FT|27898-6^Pathology Studies|1|SPECIMENS RECEIVED:||||||F|||20100507162331
OBX|2|FT|27898-6^Pathology Studies|2|\.br\||||||F|||20100507162331
OBX|3|FT|27898-6^Pathology Studies|3|A: Bone Marrow Aspirate||||||F|||20100507162331
OBX|4|FT|27898-6^Pathology Studies|4|B: Bone Marrow biopsy||||||F|||20100507162331
OBX|5|FT|27898-6^Pathology Studies|5|\.br\||||||F|||20100507162331
OBX|6|FT|27898-6^Pathology Studies|6|FINAL DIAGNOSIS:||||||F|||20100507162331
OBX|7|FT|27898-6^Pathology Studies|7|\.br\||||||F|||20100507162331
OBX|8|FT|27898-6^Pathology Studies|8|Peripheral blood, bone marrow aspirate and biopsy showing:||||||F|||20100507162331
OBX|9|FT|27898-6^Pathology Studies|9|1.	Findings consistent with mixed phenotype acute leukemia, B/myeloid.||||||F|||20100507162331
OBX|10|FT|27898-6^Pathology Studies|10|\.br\||||||F|||20100507162331
OBX|11|FT|27898-6^Pathology Studies|11|2.   Cytogenetics pending||||||F|||20100507162331
OBX|12|FT|27898-6^Pathology Studies|12|\.br\||||||F|||20100507162331
OBX|13|FT|27898-6^Pathology Studies|13|/mhp||||||F|||20100507162331
OBX|14|FT|27898-6^Pathology Studies|14|\.br\||||||F|||20100507162331
OBX|15|FT|27898-6^Pathology Studies|15|Case Pathologist: Dr. XXX||||||F|||20100507162331
OBX|16|FT|27898-6^Pathology Studies|16|\.br\||||||F|||20100507162331
OBX|17|FT|27898-6^Pathology Studies|17|\.br\||||||F|||20100507162331
OBX|18|FT|27898-6^Pathology Studies|18|Electronically authorized by MMM||||||F|||20100507162331
OBX|19|FT|27898-6^Pathology Studies|19|for Dr. XXX||||||F|||20100507162331
OBX|20|FT|27898-6^Pathology Studies|20|May 7, 2010 16:23:30||||||F|||20100507162331
OBX|21|FT|27898-6^Pathology Studies|21|\.br\||||||F|||20100507162331
OBX|22|FT|27898-6^Pathology Studies|22|CLINICAL SUMMARY AS PROVIDED BY SUBMITTING PHYSICIAN:||||||F|||20100507162331
OBX|23|FT|27898-6^Pathology Studies|23|\.br\||||||F|||20100507162331
OBX|24|FT|27898-6^Pathology Studies|24|\.br\||||||F|||20100507162331
OBX|25|FT|27898-6^Pathology Studies|25|Fifty-four year old man with known history of non-Hodgkin's lymphoma treated||||||F|||20100507162331
OBX|26|FT|27898-6^Pathology Studies|26|approximately two years ago.  Currently presents with thrombocytopenia and||||||F|||20100507162331
OBX|27|FT|27898-6^Pathology Studies|27|constitutional symptoms.||||||F|||20100507162331
OBX|28|FT|27898-6^Pathology Studies|28|\.br\||||||F|||20100507162331
OBX|29|FT|27898-6^Pathology Studies|29|PERIPHERAL BLOOD FINDINGS:||||||F|||20100507162331
OBX|30|FT|27898-6^Pathology Studies|30|\.br\||||||F|||20100507162331
OBX|31|FT|27898-6^Pathology Studies|31|\.br\||||||F|||20100507162331
OBX|32|FT|27898-6^Pathology Studies|32|CBC \T\ Differential||||||F|||20100507162331
OBX|33|FT|27898-6^Pathology Studies|33|WBC Count              9.6      [4.0-11.0]    giga/L||||||F|||20100507162331
OBX|34|FT|27898-6^Pathology Studies|34|Corrected for NRBCs||||||F|||20100507162331
OBX|35|FT|27898-6^Pathology Studies|35|RBC Count              4.27     [4.20-5.80]   tera/L||||||F|||20100507162331
OBX|36|FT|27898-6^Pathology Studies|36|Hemoglobin             135      [135-170]     g/L||||||F|||20100507162331
OBX|37|FT|27898-6^Pathology Studies|37|Hematocrit          *  0.38     [0.40-0.50]||||||F|||20100507162331
OBX|38|FT|27898-6^Pathology Studies|38|MCV                    89       [82-98]       fL||||||F|||20100507162331
OBX|39|FT|27898-6^Pathology Studies|39|\.br\||||||F|||20100507162331
OBX|40|FT|27898-6^Pathology Studies|40|\.br\||||||F|||20100507162331
OBX|41|FT|27898-6^Pathology Studies|41|RDW                    14.2     [11.0-15.0]   %||||||F|||20100507162331
OBX|42|FT|27898-6^Pathology Studies|42|Platelet Count      ** 17       [150-400]     giga/L||||||F|||20100507162331
OBX|43|FT|27898-6^Pathology Studies|43|Neutrophils            4.61     [2.0-8.0]     giga/L||||||F|||20100507162331
OBX|44|FT|27898-6^Pathology Studies|44|Eosinophils            0.10     [0.0-0.7]     giga/L||||||F|||20100507162331
OBX|45|FT|27898-6^Pathology Studies|45|Lymphocytes         *  4.23     [1.2-3.5]     giga/L||||||F|||20100507162331
OBX|46|FT|27898-6^Pathology Studies|46|Monocytes              0.29     [0.2-1.0]     giga/L||||||F|||20100507162331
OBX|47|FT|27898-6^Pathology Studies|47|Blast Cells         *  0.38     [0]           giga/L||||||F|||20100507162331
OBX|48|FT|27898-6^Pathology Studies|48|NRBC Absolute       *  0.2      [0]           giga/L||||||F|||20100507162331
OBX|49|FT|27898-6^Pathology Studies|49|RBC Morphology         Normal||||||F|||20100507162331
OBX|50|FT|27898-6^Pathology Studies|50|\.br\||||||F|||20100507162331
OBX|51|FT|27898-6^Pathology Studies|51|Reticulocyte Count||||||F|||20100507162331
OBX|52|FT|27898-6^Pathology Studies|52|Retic Count            36       [10-90]       giga/L||||||F|||20100507162331
OBX|53|FT|27898-6^Pathology Studies|53|Immature Retic Fraction||||||F|||20100507162331
OBX|54|FT|27898-6^Pathology Studies|54|13.1     [2.3-13.4]    %||||||F|||20100507162331
OBX|55|FT|27898-6^Pathology Studies|55|Red cell and neutrophil morphology is unremarkable. There is||||||F|||20100507162331
OBX|56|FT|27898-6^Pathology Studies|56|thrombocytopenia with occasional large platelet form. A small number of||||||F|||20100507162331
OBX|57|FT|27898-6^Pathology Studies|57|circulating blasts are present. Large granular and atypical lymphocytes are||||||F|||20100507162331
OBX|58|FT|27898-6^Pathology Studies|58|frequent.||||||F|||20100507162331
OBX|59|FT|27898-6^Pathology Studies|59|\.br\||||||F|||20100507162331
OBX|60|FT|27898-6^Pathology Studies|60|BONE MARROW GROSS DESCRIPTION:||||||F|||20100507162331
OBX|61|FT|27898-6^Pathology Studies|61|\.br\||||||F|||20100507162331
OBX|62|FT|27898-6^Pathology Studies|62|Received is a single container of B+ fixative from patient "EXCELLERIS, HHPATIENT"||||||F|||20100507162331
OBX|63|FT|27898-6^Pathology Studies|63|The specimen consists of a core of tan bony tissue measuring 1.4||||||F|||20100507162331
OBX|64|FT|27898-6^Pathology Studies|64|x up to 0.2 cm.  Submitted in toto.||||||F|||20100507162331
OBX|65|FT|27898-6^Pathology Studies|65|\.br\||||||F|||20100507162331
OBX|66|FT|27898-6^Pathology Studies|66|/ds||||||F|||20100507162331
OBX|67|FT|27898-6^Pathology Studies|67|\.br\||||||F|||20100507162331
OBX|68|FT|27898-6^Pathology Studies|68|Bone marrow performed by DrAAA||||||F|||20100507162331
OBX|69|FT|27898-6^Pathology Studies|69|\.br\||||||F|||20100507162331
OBX|70|FT|27898-6^Pathology Studies|70|BONE MARROW MICROSCOPY:||||||F|||20100507162331
OBX|71|FT|27898-6^Pathology Studies|71|\.br\||||||F|||20100507162331
OBX|72|FT|27898-6^Pathology Studies|72|\.br\||||||F|||20100507162331
OBX|73|FT|27898-6^Pathology Studies|73|Neutrophils     *  0.06     [0.22-0.42]   fraction||||||F|||20100507162331
OBX|74|FT|27898-6^Pathology Studies|74|Myelocytes         0.01     [0.0-0.10]    fraction||||||F|||20100507162331
OBX|75|FT|27898-6^Pathology Studies|75|Blast Cells     *  0.85     [0.0-0.02]    fraction||||||F|||20100507162331
OBX|76|FT|27898-6^Pathology Studies|76|Lymphocytes        0.06     [0.04-0.16]   fraction||||||F|||20100507162331
OBX|77|FT|27898-6^Pathology Studies|77|Erythroblast    *  0.02     [0.16-0.40]   fraction||||||F|||20100507162331
OBX|78|FT|27898-6^Pathology Studies|78|\.br\||||||F|||20100507162331
OBX|79|FT|27898-6^Pathology Studies|79|BONE MARROW:||||||F|||20100507162331
OBX|80|FT|27898-6^Pathology Studies|80|The bone marrow aspirate is an excellent granular specimen.  Granules||||||F|||20100507162331
OBX|81|FT|27898-6^Pathology Studies|81|packed with leukemic cells that account for 85%maroow cellularity.  Blasts||||||F|||20100507162331
OBX|82|FT|27898-6^Pathology Studies|82|are large with irregular nuclear outlines, moderate NC ratio, occasional||||||F|||20100507162331
OBX|83|FT|27898-6^Pathology Studies|83|prominent single nucleolus, and agranular cytoplasm. Trilineage||||||F|||20100507162331
OBX|84|FT|27898-6^Pathology Studies|84|hematopoiesis is almost completely replaced by leukemic infiltrate with||||||F|||20100507162331
OBX|85|FT|27898-6^Pathology Studies|85|only an occasional erythroid and myeloid precursors found.  Iron stain||||||F|||20100507162331
OBX|86|FT|27898-6^Pathology Studies|86|shows normal iron stores and no ring sideroblasts.||||||F|||20100507162331
OBX|87|FT|27898-6^Pathology Studies|87|\.br\||||||F|||20100507162331
OBX|88|FT|27898-6^Pathology Studies|88|The biopsy is an excellent specimen. Cellularity is more than 90% due to||||||F|||20100507162331
OBX|89|FT|27898-6^Pathology Studies|89|leukemic infiltrate. Trilineage hematopoiesis is effaced. Blasts are large||||||F|||20100507162331
OBX|90|FT|27898-6^Pathology Studies|90|with prominent eosinophilic nucleoli.||||||F|||20100507162331
OBX|91|FT|27898-6^Pathology Studies|91|Flow cytometry shows presence of blasts positive for CD34, HLA-DR, TDT, MPO||||||F|||20100507162331
OBX|92|FT|27898-6^Pathology Studies|92|and CD79a consistent with acute leukemia of mixed lineage, B/myeloid.||||||F|||20100507162331
OBX|93|FT|27898-6^Pathology Studies|93|This is an unusual case of acute mixed phenotype leukemia presenting in a||||||F|||20100507162331
OBX|94|FT|27898-6^Pathology Studies|94|patient with recent history of non-Hodgkin's lymphoma. The relation of||||||F|||20100507162331
OBX|95|FT|27898-6^Pathology Studies|95|current leukemia to the previous lymphoma or it's treatment is unclear.||||||F|||20100507162331
OBX|96|FT|27898-6^Pathology Studies|96|Cytogenetics and molecular studies are pending and would be of interest for||||||F|||20100507162331
OBX|97|FT|27898-6^Pathology Studies|97|possible MLL gene involvement.||||||F|||20100507162331
OBX|98|FT|27898-6^Pathology Studies|98|\.br\||||||F|||20100507162331
]]></Message><Message MsgID="4"><![CDATA[MSH|^~\&|PATHL7|FHAM|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516832|P|2.3|||ER|AL
PID||9876432456|SM00000426||EXCELLERIS^GPATIENT||19750926|M|||||(604)687-7507
ORC|RE||10-00085555-HP-99|||||||||90909^MDCARE^BOB
OBR|1||10-00085555-HP-99|HP^Hematology Panel|R|20100512163300|20100512163300|||||||20100512163300||90909^MDCARE^BOB||||||20100512163800||HAEM1|F||^^^^^R|90909^MDCARE^BOB
OBX|1|ST|30313-1^Hemoglogin (arterial blood)||130|g/L||N|||F|||20100512163300
ORC|RE||10-00085555-BGAS-99|||||||||90909^MDCARE^BOB
OBR|2||10-00085555-BGAS-99|BGAS^Blood Gases|R|20100512163300|20100512163300|||||||20100512163300||90909^MDCARE^BOB||||||20100512163800||CHEM3.5|F||^^^^^R|90909^MDCARE^BOB
OBX|1|ST|2744-1^Arterial pH||7.38||7.35-7.45|N|||F|||20100512163800
OBX|2|ST|2019-8^Arterial pCO2||42|mmHg|35-45|N|||F|||20100512163800
OBX|3|ST|2703-7^Arterial pO2||98|mmHg|83-108|N|||F|||20100512163800
OBX|4|ST|1960-4^Arterial HCO3||22|mmol/L|22-26|N|||F|||20100512163800
OBX|5|ST|1925-7^Arterial Base Excess||2|mmol/L|-4 to 3|N|||F|||20100512163800
OBX|6|ST|2708-6^Arterial O2 Saturation||95|%|94-98|N|||F|||20100512163800
ORC|RE||10-00085555-BCHEM-99|||||||||90909^MDCARE^BOB
OBR|3||10-00085555-BCHEM-99|BCHEM^Whole Blood Analysis|R|20100512163300|20100512163300|||||||20100512163300||90909^MDCARE^BOB||||||20100512163800||CHEM3.7|F||^^^^^R|90909^MDCARE^BOB
OBX|1|ST|15074-8^Glucose||5.0|mmol/L|3.6-8.3|N|||F|||20100512163300
OBX|2|ST|2947-0^Sodium||142|mmol/L|135-145|N|||F|||20100512163300
OBX|3|ST|6298-4^Potassium||4.0|mmol/L|3.5-5.0|N|||F|||20100512163300
OBX|4|ST|32693-4^Lactate||2.0|mmol/L|0.5-2.2|N|||F|||20100512163300
OBX|5|ST|47598-8^Calcium Ionized Adjusted To pH 7.4||1.30|mmol/L|1.15-1.32|N|||F|||20100512163300
NTE|||Sample pH within range 7.2 - 7.6 Ionized Calcium normalized\.br\to pH 7.4
]]></Message><Message MsgID="5"><![CDATA[MSH|^~\&|PATHL7|VIHA|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516833|P|2.3|||ER|AL
PID||9222456789|3042561||EXCELLERIS^JJCHILD||19950414|M|||||(250)658-1122
ORC|RE||10-999-001666-ACARN-0|||||||||90909^MDCARE^BOB
OBR|1||10-999-001666-ACARN-0|ACARN^Acyl Carnitine|RT|20100713081500|20100713074200|||||||20100713081500||90909^MDCARE^BOB||||||20100808112546||REFER1|F||^^^^^RT|90909^MDCARE^BOB~00000^B.C. Childrens' Hospital^Health Records Dept.
OBX|1|FT|X50335^Acyl Carnitine Blood Dot||Bloodspot, Acylcarnitine, (umol/L); \.br\\.br\Date of Assay:14Jul2010  \.br\\.br\Carnitine:24.9\.br\Reference Range (umol/L): 10.9 - 29.8\.br\\.br\\.br\C2:18.6\.br\Reference Range (umol/L): 7.1 - 28.0\.br\\.br\C3:1.58\.br\Reference Range (umol/L): 0.60 - 2.87\.br\\.br\C4:0.32\.br\Reference Range (umol/L): 0.12 - 0.47\.br\\.br\C5:1:0.02 \.br\Reference Range (umol/L): less than 0.08\.br\\.br\C5:0.14\.br\Reference Range (umol/L): 0.05 - 0.24\.br\\.br\C4 OH:0.12\.br\Reference Range (umol/L): 0.05 - 0.27\.br\\.br\C6:0.04\.br\Reference Range (umol/L): 0.02 - 0.12\.br\\.br\C5 OH:0.29\.br\Reference Range (umol/L): 0.05 - 0.40\.br\\.br\C8:1:0.23   H\.br\Reference Range (umol/L): less than 0.22\.br\\.br\C8:0.05\.br\Reference Range (umol/L):0.01 - 0.12\.br\\.br\Malonyl:0.10   H\.br\Reference Range (umol/L): less than 0.06\.br\\.br\C10:1:0.05\.br\Reference Range (umol/L): less than 0.12\.br\\.br\C10:0.05\.br\Reference Range (umol/L): 0.03 - 0.17\.br\\.br\C4DC:0.19\.br\Reference Range (umol/L): 0.07 - 0.30\.br\\.br\Glutaryl DC:0.05\.br\Reference Range (umol/L): less than 0.07\.br\\.br\C12:1:0.04\.br\Reference Range (umol/L): less than 0.16\.br\\.br\C12:0.15\.br\Reference Range (umol/L): 0.04 - 0.42\.br\\.br\C6DC:0.01\.br\Reference Range (umol/L): less than 0.05\.br\\.br\C12:1OH:0.02\.br\Reference Range (umol/L): less than 0.08\.br\\.br\C12 OH:0.02\.br\Reference Range (umol/L): less than 0.07\.br\\.br\C14:2:0.08\.br\Reference Range (umol/L): 0.02 - 0.16\.br\\.br\C14:1:0.23\.br\Reference Range (umol/L): 0.08 - 0.81\.br\\.br\C14:0.19\.br\Reference Range (umol/L): 0.06 - 0.41\.br\\.br\C8DC:0.01\.br\Reference Range (umol/L): less than 0.05\.br\\.br\C14:1 OH:0.04\.br\Reference Range (umol/L): less than 0.08\.br\\.br\C14 OH:0.03\.br\Reference Range (umol/L): less than 0.05\.br\\.br\C16:0.77\.br\Reference Range (umol/L): 0.33 - 1.52\.br\\.br\C16:1 OH0.06\.br\Reference Range (umol/L): less than 0.11\.br\\.br\C16 OH:0.02\.br\Reference Range (umol/L): less than 0.06\.br\\.br\C18:2:0.41\.br\Reference Range (umol/L):0.13 - 0.50\.br\\.br\C18:1:1.06\.br\Reference Range (umol/L): 0.57 - 2.04\.br\\.br\C18:0.60\.br\Reference Range (umol/L): 0.23 - 1.00\.br\\.br\C18:2 OH:0.01\.br\Reference Range (umol/L): less than 0.03\.br\\.br\C18:1 OH:0.02\.br\Reference Range (umol/L): less than 0.04\.br\\.br\C16DC:None Detected\.br\Reference Range (umol/L): less than 0.03\.br\\.br\C18:1 DC:0.01\.br\Reference Range (umol/L): less than 0.04\.br\\.br\Total Acyl Carnitines:23.7\.br\Reference Range (umol/L): 9.8 - 34.4\.br\\.br\Total Carnitine:48.5\.br\Reference Range (umol/L): 21.8 - 62.5\.br\\.br\Fraction:0.49\.br\Reference Range (umol/L): 0.38 - 0.62\.br\\.br\C8/C10 Ratio:0.97\.br\Reference Range (umol/L): 0.31 - 1.11\.br\\.br\C3/C2 Ratio:0.09\.br\Reference Range (umol/L): 0.04 - 0.18\.br\\.br\C3/C16 Ratio:2.10\.br\Reference Range (umol/L): 0.53 - 3.36\.br\\.br\C8/C2 Ratio:None Detected\.br\Reference Range (umol/L): less than 0.02\.br\\.br\C0/(C16+C18) Ratio:18.10\.br\Reference Range (umol/L): 6.86 - 27.26\.br\\.br\(C16+C18:1)/C2 Ratio:0.10\.br\Reference Range (umol/L): 0.09 - 0.25\.br\\.br\C14:1/C12:1 Ratio:5.70\.br\Reference Range (umol/L): less than 16.39\.br\\.br\C16 OH/C16 Ratio:0.03\.br\Reference Range (umol/L): less than 0.07|||N|||F|||20100808112546
NTE|||Analyzed at BC Children's Hospital
OBX|2|FT|X10011^Pathologist Comments||Comment: Unremarkable acylcarnitine profile in bloodspot. No evidence for a fatty acid oxidation disorder.\.br\Dr. VVV, MD, FRCP(C), FCCMG\.br\Biochemical Genetics Lab 1-604-875-23|||N|||F|||20100808112546
]]></Message><Message MsgID="6"><![CDATA[MSH|^~\&|PATHL7|PRH|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516834|P|2.3|||ER|AL
PID||9040555789|PR00049945||EXCELLERIS^KPATIENT||19700603|M|||||(604)212-1122
ORC|RE||1108:UA00077R-22200-GCM-1|||||||||90909^MDCARE^BOB
OBR|1||1108:UA00077R-22200-GCM-1|GCM^General Information|||20100811151700|||||||20100820090100||90909^MDCARE^BOB||||||20100820090100||GENERAL|F|||90909^MDCARE^BOB
NTE|||Provinical Health Care No. : 9040555789
ORC|RE||1108:UA00077R-22200-UPH-1|||||||||90909^MDCARE^BOB
OBR|2||1108:UA00077R-22200-UPH-1|UPH^Urine pH Timed|||20100811151700|||||||20100820090100||90909^MDCARE^BOB||||||20100820090100||CHEM9|F|||90909^MDCARE^BOB
OBX|1|NM|27378-9^pH by Meter||5.5|||N|||F|||20100820090100
]]></Message><Message MsgID="7"><![CDATA[MSH|^~\&|PATHL7|BCB|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516835|P|2.3|||ER|AL
PID||9101321654|||EXCELLERIS^BPATIENT||19430102|F|||||604-658-2107
ORC|RE||T10-1212111-URC-0|||||||||90909^MDCARE^BOB
OBR|1||T10-1212111-URC-0|URC^Urine Culture||20100814162800|20100813162800|||||||20100814162800||90909^MDCARE^BOB||101384630||||20100818103200||MICRO3|F|||90909^MDCARE^BOB~H06284^PITT MEADOWS^MEDICAL CLINIC
NTE|||\.br\\.br\Reviewed by Microbiologist.(604-507-5000).
OBX|1|FT|19803-6^Site||Urine, Midstream||||||F|||20100814162900
OBX|2|FT|6463-4^Organism|1|>100 mega CFU/Litre Klebsiella pneumoniae|||A|||F|||20100818085300
OBX|3|FT|28-1^Ampicillin|1|R||||||F|||20100818085300
OBX|4|FT|20-8^Amoxicillin-Clavulanate|1|I||||||F|||20100818085300
OBX|5|FT|76-0^Cefazolin|1|S||||||F|||20100818085300
OBX|6|FT|80-2^Cefixime|1|S||||||F|||20100818085300
OBX|7|FT|108-1^Cefotaxime|1|S||||||F|||20100818085300
OBX|8|FT|412-7^Piperacillin-Tazobactam|1|S||||||F|||20100818085300
OBX|9|FT|6652-2^Meropenem|1|S||||||F|||20100818085300
OBX|10|FT|516-5^Trimethoprim-Sulfa|1|S||||||F|||20100818085300
OBX|11|FT|185-9^Ciprofloxacin|1|S||||||F|||20100818085300
OBX|12|FT|267-5^Gentamicin|1|S||||||F|||20100818085300
OBX|13|FT|12-5^Amikacin|1|S||||||F|||20100818085300
OBX|14|FT|363-2^Nitrofurantoin|1|R||||||F|||20100818085300
OBX|15|FT|6463-4^Organism|2|>100 mega CFU/Litre Escherichia coli|||A|||F|||20100818085300
OBX|16|FT|28-1^Ampicillin|2|S||||||F|||20100818085300
OBX|17|FT|20-8^Amoxicillin-Clavulanate|2|S||||||F|||20100818085300
OBX|18|FT|80-2^Cefixime|2|S||||||F|||20100818085300
OBX|19|FT|108-1^Cefotaxime|2|S||||||F|||20100818085300
OBX|20|FT|412-7^Piperacillin-Tazobactam|2|S||||||F|||20100818085300
OBX|21|FT|6652-2^Meropenem|2|S||||||F|||20100818085300
OBX|22|FT|516-5^Trimethoprim-Sulfa|2|S||||||F|||20100818085300
OBX|23|FT|185-9^Ciprofloxacin|2|R||||||F|||20100818085300
OBX|24|FT|267-5^Gentamicin|2|S||||||F|||20100818085300
OBX|25|FT|12-5^Amikacin|2|S||||||F|||20100818085300
OBX|26|FT|363-2^Nitrofurantoin|2|S||||||F|||20100818085300
]]></Message><Message MsgID="8"><![CDATA[MSH|^~\&|PATHL7|VCH|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516836|P|2.3|||ER|AL
PID||9080060306|2325603||EXCELLERIS^FPATIENT||19210523|F|||||604-878-2669
ORC|RE||M121288-13951597-URC-1|||||||||90909^MDCARE^BOB
OBR|1||M121288-13951597-URC-1|URC^Urine Culture||20100830164800|20100830161500|||||||20100830164800||90909^MDCARE^BOB||||||20100902132501||MICRO3|F|||90909^MDCARE^BOB
OBX|1|FT|19803-6^Site||Urine||||||F|||20100830164831
OBX|2|FT|X10095^Special Requests||None||||||F|||20100830164831
OBX|3|FT|X10114^Report Status||Final\.br\02Sep2010||||||F|||20100902132501
OBX|4|FT|6463-4^Culture|1|>100 million CFU/L E. coli||||||F|||20100902080251
OBX|5|FT|28-1^Ampicillin|1|S||||||F|||20100901090918
OBX|6|FT|20-8^Amoxicillin-Clavulanate|1|S||||||F|||20100901090918
OBX|7|FT|X10042^Cephalothin/Cephalexin|1|S||||||F|||20100901090918
OBX|8|FT|145-3^Cefuroxime Parenteral|1|S||||||F|||20100901090918
OBX|9|FT|412-7^Piperacillin-Tazobactam|1|S||||||F|||20100901090918
OBX|10|FT|279-0^Imipenem|1|S||||||F|||20100901090918
OBX|11|FT|516-5^Trimethoprim-Sulfa|1|S||||||F|||20100901090918
OBX|12|FT|185-9^Ciprofloxacin|1|S||||||F|||20100901090918
OBX|13|FT|267-5^Gentamicin|1|S||||||F|||20100901090918
OBX|14|FT|496-0^Tetracycline|1|S||||||F|||20100901090918
OBX|15|FT|363-2^Nitrofurantoin|1|S||||||F|||20100901090918
OBX|16|FT|6463-4^Culture|2|80 million CFU/L Enterococcus faecalis||||||F|||20100902080251
OBX|17|FT|28-1^Ampicillin|2|S||||||F|||20100902080251
OBX|18|FT|185-9^Ciprofloxacin|2|R||||||F|||20100902080251
OBX|19|FT|496-0^Tetracycline|2|R||||||F|||20100902080251
OBX|20|FT|363-2^Nitrofurantoin|2|S||||||F|||20100902080251
]]></Message><Message MsgID="9"><![CDATA[MSH|^~\&|PATHL7|PHC|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516837|P|2.3|||ER|AL
PID||9142767676|4384129||EXCELLERIS^HPATIENT||19460810|F|||||250-876-4567
ORC|RE||F121266-14100890-RUE-1|||||||||90909^MDCARE^BOB
OBR|1||F121266-14100890-RUE-1|RUE^Urine Immunofixation Random||20100924104500|20100924104300|||||||20100924112500||90909^MDCARE^BOB||||||20100928172644||CHEM10|F|||90909^MDCARE^BOB
OBX|1|NM|2888-6^Urine Protein||0.05|g/L|||||F|||20100924122733
OBX|2|FT|X10011^Pathologist Comments||Negative for BJ proteinuria.\.br\Dr. NNN||||||F|||20100928172644
]]></Message><Message MsgID="10"><![CDATA[MSH|^~\&|PATHL7|FHAM|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516838|P|2.3|||ER|AL
PID||9876432456|BH02502488||EXCELLERIS^GPATIENT||19750926|M|||||(604)687-7507
ORC|RE||10-9999BME3-HP-12|||||||||90909^MDCARE^BOB
OBR|1||10-9999BME3-HP-12|HP^Hematology Panel||20101028000300|20101028060000|||||||20101028070400||90909^MDCARE^BOB||||||20101028125400||HAEM1|F|||90909^MDCARE^BOB
NTE|||List of add on tests: BME\.br\Requested by: PATHOLOGIST\.br\BONE MARROW PATIENT
OBX|1|ST|12227-5^WBC||36.3|x10*9/L|4.0-11.0|H|||F|||20101028092000
NTE|||****   CORRECTED RESULT  ****\.br\---  22/10/10 0919 ---\.br\WBC previously reported as: 38.8  H x10*9/L\.br\\.br\\.br\Reason: PRESENCE OF NRBCS
OBX|2|ST|789-8^RBC||2.72|x10*12/L|3.50-5.00|L|||F|||20101028072500
OBX|3|ST|718-7^Hemoglobin||86|g/L|115-160|L|||F|||20101028072500
OBX|4|ST|4544-3^Hematocrit||0.25|L/L|0.35-0.47|L|||F|||20101028072500
OBX|5|ST|787-2^MCV||94|fl|80-100|N|||F|||20101028072500
OBX|6|ST|777-3^Platelet Count||197|x10*9/L|150-400|N|||F|||20101028072500
OBX|7|ST|751-8^Neutrophils||18.7|x10*9/L|2.0-8.0|H|||F|||20101028092000
OBX|8|ST|731-0^Lymphocytes||3.4|x10*9/L|1.0-4.0|N|||F|||20101028092000
OBX|9|ST|742-7^Monocytes||12.5|x10*9/L|0.1-0.8|H|||F|||20101028092000
OBX|10|ST|711-2^Eosinophils||< 0.1|x10*9/L|<0.6|N|||F|||20101028092000
OBX|11|ST|704-7^Basophils||< 0.1|x10*9/L|<0.2|N|||F|||20101028092000
OBX|12|ST|763-3^Band Neutrophils||Incr'd|||H|||F|||20101028093400
OBX|13|ST|739-3^Metamyelocytes||1.3|x10*9/L|0.0|H|||F|||20101028092000
OBX|14|ST|748-4^Myelocytes||0.4|x10*9/L|0.0|H|||F|||20101028092000
OBX|15|ST|771-6^Nucleated RBC||2.5|x10*9/L|None Seen|H|||F|||20101028092000
OBX|16|ST|X10163^Toxic Changes||Present|||H|||F|||20101028093400
OBX|17|ST|10378-8^Polychromasia||+2|||H|||F|||20101028125200
OBX|18|ST|703-9^Basophilic Stippling||Present|||H|||F|||20101028125400
OBX|19|ST|9317-9^Platelet Estimate||Normal|||N|||F|||20101028093400
ORC|RE||10-9999BME3-RET-12|||||||||90909^MDCARE^BOB
OBR|2||10-9999BME3-RET-12|RET^Absolute Retic||20101028000300|20101028060000|||||||20101028070400||90909^MDCARE^BOB||||||20101028125400||HAEM1|F|||90909^MDCARE^BOB
NTE|||List of add on tests: BME\.br\Requested by: PATHOLOGIST\.br\BONE MARROW PATIENT
OBX|1|ST|14196-0^Reticulocytes||166|x10*9/L|35-120|H|||F|||20101028110300
]]></Message><Message MsgID="11"><![CDATA[MSH|^~\&|PATHL7|VML|HTTPCLIENT|vendor1|20101216161517||ORU^R01|ENG20101216161516839|P|2.3|||ER|AL
PID||9012050878|||EXCELLERIS^CCPATIENT||19391016|M|||||(250)764-6666
ORC|RE||101212999-GCM-0|||||||||90909^MDCARE^BOB
OBR|1||101212999-GCM-0|GCM^General Information||20101130102341|20101130102341|||||||20101130102341||90909^MDCARE^BOB||||||20101130161639||GENERAL|F|||90909^MDCARE^BOB
NTE|||RESULTS VERIFIED\.br\Prelim results to be phoned to Dr Office  \.br\\.br\Results to be PHD/FAXED to Doctors Office.  \.br\\.br\faxed Dr's BBB and SSS; phoned Dr.SSS's Nov 30 2:20 em  \.br\\.br\PATHOLOGIST COMMENT\.br\Macrocytic anemia with mild thrombocytopenia.  The blood film does not suggest a specific cause i.e. no neoplastic cells, overt polychromasia, dysplastic changes, etc.  The ddx includes B12 deficiency, liver disease, marrow pathology, medication or EtOH effect, blood loss, and combinations thereof.  Follow up suggested.\.br\MD  \.br\
ORC|RE||101212999-HP-0|||||||||90909^MDCARE^BOB
OBR|2||101212999-HP-0|HP^Hematology Panel|R|20101130102511|20101130102341|||||||20101130102341||90909^MDCARE^BOB||||||20101130161639||HAEM1|R||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|12227-5^WBC||6.3|*10E 9/L|4.0 - 10.0|N|||F|||20101130102341
OBX|2|NM|789-8^RBC||2.40|*10E12/L|4.60 - 6.20|L|||F|||20101130102341
OBX|3|NM|718-7^Hemoglobin||88|g/L|140 - 180|!L|||F|||20101130102341
OBX|4|NM|4544-3^Hematocrit||0.256|L/L|0.420 - 0.520|L|||F|||20101130102341
OBX|5|NM|787-2^MCV||107|fl|80 - 97|H|||F|||20101130102341
OBX|6|NM|785-6^MCH||36.7|pg|27.0 - 31.0|H|||F|||20101130102341
OBX|7|NM|786-4^MCHC||344|g/L|320 - 360|N|||F|||20101130102341
OBX|8|NM|777-3^Platelet Count||139|*10E 9/L|150 - 400|L|||F|||20101130102341
OBX|9|NM|751-8^Neutrophils||3.5|*10E 9/L|2.0 - 7.5|N|||F|||20101130102341
OBX|10|NM|731-0^Lymphocytes||2.0|*10E 9/L|1.5 - 4.0|N|||F|||20101130102341
OBX|11|NM|742-7^Monocytes||0.6|*10E 9/L|0.2 - 0.8|N|||F|||20101130102341
OBX|12|NM|711-2^Eosinophils||0.3|*10E 9/L|0.0 - 0.4|N|||F|||20101130102341
OBX|13|NM|704-7^Basophils||0.0|*10E 9/L|0.0 - 0.1|N|||F|||20101130102341
OBX|14|ST|38892-6^Anisocytosis||Slight|||N|||F|||20101130102341
OBX|15|ST|30424-6^Macrocytosis||+2|||N|||F|||20101130102341
OBX|16|ST|10378-8^Polychromasia||Slight|||N|||F|||20101130102341
OBX|17|ST|9317-9^Platelet Estimate||Normal|||N|||F|||20101130102341
ORC|RE||101212999-RET-0|||||||||90909^MDCARE^BOB
OBR|3||101212999-RET-0|RET^Absolute Retic|R|20101130130324|20101130102341|||||||20101130102341||90909^MDCARE^BOB||||||20101130161639||HAEM1|F||^^^^^R|90909^MDCARE^BOB
OBX|1|NM|14196-0^Reticulocytes||97|*10E 9/L|25 - 100|N|||F|||20101130102341
]]></Message></HL7Messages>
